vepdegestrant

News

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

AstraZeneca stakes a claim to first-line treatment of HR+ breast cancer with its oral SERD, as Arvinas/Pfizer reveal their second-line data.

News

Pfizer's new drug data in breast cancer draws muted response

Pfizer and Arvinas' much-anticipated oral SERD vepdegestrant for breast cancer missed a key endpoint in its first phase 3 readout.

News

Data cues up AZ oral SERD filing in first-line breast cancer

AstraZeneca could be the first to bring an oral SERD to market in first-line breast cancer after camizestrant hit the mark in a phase 3 trial.

News

11 blockbuster drugs to look out for in 2025

Clarivate has revealed 11 drugs due to launch in 2025 that could top $1 billion in annual sales or be clinical 'game changers' in the next five years.

ASCO 25: AZ pitches upfront oral SERD use in breast cancer

Pfizer's new drug data in breast cancer draws muted response

Data cues up AZ oral SERD filing in first-line breast cancer

11 blockbuster drugs to look out for in 2025

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

vepdegestrant

Editor's Picks